黄芪甲苷抗肾纤维化的相关分子机制研究  

Advances in Molecular Mechanism of Astragaloside IV on Renal Fibrosis

作　　者：卢海霞 覃柞莲 陆丽娟 吴炳瑶 谢丽[1] 李丽[1] LU Haixia;QIN Zuolian;LU Lijuan;WU Bingyao;XIE Li;LI Li(The First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530001,China)

机构地区：[1]广西中医药大学第一附属医院,广西南宁530001

出　　处：《西部中医药》2022年第3期145-151,共7页Western Journal of Traditional Chinese Medicine

摘　　要：通过综述肾纤维化的发生机制、黄芪甲苷(astragaloside IV,AS-IV)抗肾间质纤维化的分子机制及含AS-IV的抗肾纤维进程的相关中成药及注射剂探讨AS-IV抗肾纤维化的相关分子机制研究进展,指出已有研究证实AS-IV主要通过剂量依赖等方式阻止及防范足细胞凋亡及抑制肾脏纤维化。Research progress on molecular mechanism of AS-IV against renal fibrosis was discussed by reviewing the pathogenesis of renal fibrosis,molecular mechanism of AS-IV on renal interstitial fibrosis,the related Chinese patent medicine and injections containing AS-IV against the progression of renal fibrosis.The previous studies have confirmed that AS mainly prevent podocyte apoptosis and inhibit renal fibrosis in a dose dependent manner.

关 键 词：肾纤维化 分子机制 黄芪甲苷 综述 

分 类 号：R256[医药卫生—中医内科学]